Clinical Trial
Currently Recruiting
The End Brain Cancer Initative is partnering with Curis to help enroll patients in the PCNSL TakeAim Lymphoma clinical trial (CA-4948-101). Please complete the Interest Form linked below and/or reach out to the End Brain Cancer Initiative (EBCI) clinical research coordinator/patient navigator for pre-qualifications or any questions.
Shreya Prakash; shreya@endbraincancer.org - 425-436-8688
YES! I'm InterestedThis trial is evaluating a new oral drug, emavusertib, both alone and in combination with ibrutinib. The goal is to determine safe dosing, assess whether the drug effectively reaches the brain, and measure its ability to shrink tumors and slow disease progression.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) (NCT03328078)
*This medication is ORAL! No infusion chair and no refrigeration.
